November 29, 2016 / 8:25 AM / 8 months ago

Actelion shares plunge on report it eyes 'complicated' J&J deal

1 Min Read

A general view shows Swiss biotech group Actelion Headquarters in Allschwil, Switzerland, February 17, 2015.Arnd Wiegmann/File Photo

ZURICH (Reuters) - Shares in Swiss biotech company Actelion (ATLN.S) plunged on Tuesday after a report the company was not actively considering selling itself, but instead weighing a "complicated deal" to link with U.S. healthcare giant Johnson & Johnson (JNJ.N).

Actelion shares fell more than 8 percent in early trading, after having risen sharply over the last four days to value the company at about $20 billion amid takeover speculation.

Johnson & Johnson approached Actelion Chief Executive Jean-Paul Clozel expecting him to reject a takeover, so it instead has focused on another proposal to take a major stake in the Swiss company while leaving it independent, the Financial Times reported late on Monday.

Actelion declined to comment on the FT report. A Johnson & Johnson spokesman also declined comment.

Reporting by John Miller, editing by Michael Shields

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below